Lexaria Bioscience Corp. and Cannadips CBD Announce Definitive Technology Licensing agreement for CBD Oral Pouch & Dip Category
Posted on Tuesday January 14, 2020

KELOWNA, BC / ACCESSWIRE / January 14, 2020 / Lexaria Bioscience Corp. (LXRP)(LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has reached a definitive agreement to provide its patented DehydraTECHTM technology to Cannadips CBD, the Original Smokeless CBD Dip Brand. Cannadips CBD is America's leading and oldest oral pouch, similar to a Snus pouch, formulated with CBD from American hemp. Lexaria, already established as the leader in the CBD oral delivery, has been working with the Boldt Runners team behind the scenes to elevate the product experience.

Lexaria Provides Strategic Update from CEO
Posted on Thursday January 09, 2020

KELOWNA, BC / ACCESSWIRE / January 9, 2020 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces the following strategic update. "Lexaria's brightest days lie in the future, not in the past," said Chris Bunka, Chief Executive Officer of Lexaria Bioscience Corp. Lexaria achieved many things during 2019 - indeed, management feels that it achieved virtually all that it had set out to accomplish and it was its best year ever from an operational perspective.

Lexaria’s Technology Now Works in Less Than 10 Minutes
Posted on Thursday November 21, 2019

KELOWNA, BC / ACCESSWIRE / November 21, 2019 / Lexaria Bioscience Corp. (LXRP)(CSE LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has developed additional enhancements for its industry-leading DehydraTECHTM platform that delivers THC onset of action in human pilot testing in less than 10 minutes. In recent human subjective pilot tests, volunteers reported onset of THC action from edibles formulated with this latest DehydraTECH innovation in less than 10 minutes. This enhanced version is roughly twice as fast as traditional DehydraTECH and four to six times faster than generic industry formulations.

Lexaria Bioscience Appoints Gregg Smith as Senior Advisor
Posted on Tuesday November 05, 2019

KELOWNA, BC / ACCESSWIRE / November 5, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is very pleased to announce the appointment of Gregg Smith, Founder of Evolution VC Partners (www.evolutionvcp.com), as Senior Advisor. Evolution VC is a New York-based "culture tech" venture investment firm with more than 90 portfolio companies in many disruptive and emerging consumer-tech companies, including JUUL Labs, Pax Labs, Beyond Meat, Roman, Sweetgreen, Bird, New Wave Foods, Relativity Space and more. Prior to forming his investment company in 2007, Gregg spent 20 years on Wall Street as an investment banker focused on executing private equity placements with a strong focus on life sciences.